J Hepatobiliary Pancreat Sci. Prospective validation of an immunohistochemical panel glypican 3, heat shock protein 70 and glutamine synthetase in liver biopsies for diagnosis of very early hepatocellular carcinoma. Hsc70 regulates accumulation of cyclin D1 and cyclin D1-dependent protein kinase.
Mol Cell Biol. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. Genome Biol. Soluble Glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol.
Squamous cell carcinoma antigen in human liver carcinogenesis. J Clin Pathol. Mol Cancer. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma.
GP73, a novel Golgi-localized protein upregulated by viral infection. Clin Biochem. GOLPH2 expression may serve as diagnostic marker in seminomas. BMC Urol. GOLPH2 expression in renal cell cancer. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer.
A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat. Golgi phosphoprotein 2 GOLPH2 expression in liver tumors and its value as a serum marker in hepatocellular carcinomas.
Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. Significance of Golgi glyco-protein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Zhonghua Yi Xue Za Zhi. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers.
Mol Cell Proteomics. Tumor associated glycoprotein is a novel marker for poor survival in hepatocellular carcinoma. Pathol Oncol Res. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprote in Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients.
Identification of ZAG protein as a novel serologic biomarker candidate for liver cancer. Adv Mater Res. Gamma-carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochim Biophys Acta. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
Am J Gastroenterol. Significance of alpha-fetopmtein and des-gamma-carbroxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. J Gastroenterol. Specific molecular markers in hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int. Normal adult values are less than 40 micrograms mg per liter. An increase is a signal that something may be wrong. People at high risk for liver cancer are urged to have their AFP level measured every six months. Members of this group include anyone with cirrhosis of the liver and certain people with chronic hepatitis B or hepatitis C infection. However, the utility of AFP measurement is clouded by the fact that rising levels are associated with several conditions other than liver cancer.
AFP is also used to:. When the treatment is successful, AFP levels drop back to normal. Another rise suggests that the cancer has returned, Dr. Your test results may not mean you have a problem. Ask your healthcare provider what your test results mean for you. High levels of AFP may mean other cancers, including Hodgkin disease, lymphoma, and renal cell carcinoma kidney cancer.
Not all people with these cancers will have an elevated AFP. And elevated AFP levels also could be a sign of cirrhosis or chronic acute hepatitis. The test is done with a blood sample. A needle is used to draw blood from a vein in your arm or hand.
Having a blood test with a needle carries some risks. These include bleeding, infection, bruising, and feeling lightheaded. When the needle pricks your arm or hand, you may feel a slight sting or pain. Afterward, the site may be sore. If you are pregnant, your serum AFP level may be higher than normal. If you have hepatitis or cirrhosis, your AFP level may also be elevated. Skip to topic navigation.
Skip to main content. You are here: Home. Your AFP levels have not increased or decreased. This may mean your disease is stable. Your AFP levels decreased, but then later increased. This may mean your cancer has come back after you've been treated. Is there anything else I need to know about an AFP tumor marker test? References Allina Health [Internet].
Minneapolis: Allina Health; Alphafetoprotein measurement, serum; [updated Mar 29; cited Jul 25]; [about 3 screens]. Atlanta: American Cancer Society Inc. Net [Internet]. Understanding Targeted Therapy; Jan 20 [cited May 16]; [about 4 screens]. Washington D. Mayo Foundation for Medical Education and Research; c— Cancer blood tests: lab tests used in cancer diagnosis: Nov 22 [cited Jul 25]; [about 4 screens].
Diagnosis of Cancer; [cited Jul 25]; [about 2 screens]. Bethesda MD : U. Philadelphia: Trustees of the University of Pennsylvania; c Serum Tumor Markers.
0コメント